Sclerotherapy for Varicose Veins
Introduction
Sclerotherapy is a well-established, minimally invasive interventional procedure in which a chemical sclerosant agent is introduced directly into a diseased vein, inducing controlled endothelial injury, fibrosis, and subsequent obliteration of the abnormal venous segment. It represents one of the oldest and most extensively validated techniques in the management of varicose veins and associated venous insufficiency, with its clinical application dating back to the nineteenth century and its modern refinement continuing through the present era of image-guided intervention.
In contemporary interventional radiology and vascular medicine practice, sclerotherapy occupies a central role in the treatment algorithm for varicose veins, reticular veins, and telangiectasias — collectively representing a disease burden affecting a substantial proportion of the adult population worldwide. The procedure addresses not only the cosmetic concerns that frequently prompt patients to seek evaluation, but more critically, the clinical manifestations of chronic venous insufficiency, including pain, edema, skin changes, and ulceration, which carry a meaningful impact on quality of life and long-term limb health. When performed with precision and appropriate patient selection, sclerotherapy delivers durable results with minimal procedural risk and rapid return to daily activity.
Understanding Varicose Veins and Chronic Venous Insufficiency
The venous system of the lower extremity is anatomically divided into the superficial and deep venous systems, connected by perforating veins that traverse the muscular fascia. The superficial system, comprising the great saphenous vein and small saphenous vein along with their tributaries, operates under significantly lower pressures than the deep system and is dependent upon a series of bicuspid venous valves to maintain unidirectional cephalad blood flow against gravity. These valves open during muscular contraction of the calf and close during relaxation, preventing retrograde reflux of blood toward the dependent limb.
Varicose veins develop when venous valvular competence is lost — whether through primary structural degeneration, elevated intraluminal pressure, hormonal influences, or inherited connective tissue predisposition — allowing blood to reflux in a retrograde direction and pool within the superficial venous tributaries. This sustained venous hypertension causes progressive dilation, tortuosity, and elongation of the affected veins, producing the characteristic bulging, cord-like subcutaneous structures visible on clinical examination. Over time, the hydrostatic pressure transmitted to the microcirculation of the skin and subcutaneous tissues results in capillary leak, inflammatory mediator activation, and progressive tissue damage.
The clinical consequences of untreated chronic venous insufficiency progress along a well-characterized spectrum classified by the CEAP system. Early disease manifests as telangiectasias and reticular veins, advancing to varicosities with associated symptoms of aching, heaviness, pruritus, and dependent edema. In advanced stages, lipodermatosclerosis, hyperpigmentation from hemosiderin deposition, atrophie blanche, and ultimately venous leg ulceration represent end-organ consequences of sustained venous hypertension. The pathophysiology is perpetuated by incompetent perforating veins and saphenofemoral or saphenopopliteal junction reflux, which serve as the hemodynamic sources driving continued disease progression if not appropriately addressed.
Telangiectasias and reticular veins, though smaller in caliber, share the same fundamental pathophysiology of venous hypertension and valvular incompetence, differing primarily in the anatomical level — intradermal and subdermal respectively — at which the abnormal venous dilation occurs. These smaller vessel variants respond particularly well to sclerotherapy, which remains the preferred modality for their management across clinical guidelines.
Indications for the Procedure
Sclerotherapy is indicated across a broad range of venous pathology, and its application is tailored to the size, anatomical configuration, and hemodynamic characteristics of the target vessels. The primary indications include symptomatic varicose veins causing pain, heaviness, swelling, or cramps; cosmetically troublesome varicose veins, reticular veins, and telangiectasias in patients seeking definitive treatment; residual or recurrent varicosities following prior saphenous ablation procedures or surgical stripping; and venous tributary incompetence identified on duplex ultrasound evaluation.
In patients with chronic venous insufficiency complicated by skin changes or active venous ulceration, sclerotherapy of feeding varicosities and incompetent perforators contributes to the overall management strategy aimed at reducing ambulatory venous hypertension and promoting ulcer healing. Foam sclerotherapy, in particular, has expanded the treatable vessel range to include larger truncal varicosities and incompetent saphenous segments that were previously beyond the scope of liquid sclerotherapy alone.
It is essential that significant saphenofemoral or saphenopopliteal junction incompetence be identified and addressed — either through endovenous thermal ablation, mechanochemical ablation, or surgical ligation — prior to or concurrent with sclerotherapy of tributary varicosities. Failure to treat the underlying axial reflux source is a recognized cause of early recurrence and treatment failure, as persistent reflux from the junction will continue to repressurize the treated tributaries.
Pre-Procedure Preparation
A thorough clinical and duplex ultrasound assessment forms the foundation of pre-procedure preparation. Duplex ultrasonography is the diagnostic standard for mapping the venous anatomy, quantifying reflux at the saphenofemoral and saphenopopliteal junctions, identifying incompetent perforating veins, assessing deep venous patency, and characterizing the size and distribution of varicosities targeted for treatment. This hemodynamic map guides the treatment strategy and determines whether sclerotherapy alone is appropriate or whether it should be combined with or preceded by saphenous ablation.
A detailed medical history is obtained to identify contraindications, including known hypersensitivity to sclerosant agents, acute deep vein thrombosis or superficial thrombophlebitis, severe peripheral arterial disease with compromised limb perfusion, uncontrolled hypercoagulable states, pregnancy, breastfeeding, and significant systemic illness. Patients with a prior history of pulmonary embolism or deep vein thrombosis warrant particularly careful risk-benefit evaluation, and anticoagulation status must be reviewed and managed in consultation with the treating physician.
Compression stockings and ambulation play an integral role in sclerotherapy protocols. Patients are advised to bring or wear appropriate compression garments on the day of the procedure, as post-procedural graduated compression is central to optimizing treatment outcomes and minimizing complications. Patients are counseled to wear comfortable, loose-fitting clothing that allows easy access to the lower limbs, and activities that significantly elevate venous pressure — such as prolonged standing, vigorous exercise, or hot baths — are discouraged in the immediate pre-procedural period. Routine anticoagulant and antiplatelet medications are generally continued unless otherwise directed, as the risk of thrombosis associated with endothelial injury necessitates careful individualized assessment.
How the Procedure is Performed
Sclerotherapy is performed in an outpatient procedural setting and does not require general anesthesia or sedation in the majority of cases. The patient is positioned supine or with the limb slightly elevated depending on the target vessel location, and the skin overlying the treatment area is cleaned with an appropriate antiseptic solution. The proceduralist performs a final clinical and ultrasound assessment to confirm target vessel identification and plan the injection sequence, typically proceeding from the largest and most proximal vessels to the smaller, more distal tributaries.
For liquid sclerotherapy, the sclerosant agent — most commonly polidocanol or sodium tetradecyl sulfate — is prepared at an appropriate concentration determined by the caliber of the target vessel. Smaller telangiectasias typically require lower concentrations in the range of 0.1 to 0.5 percent polidocanol, while larger reticular veins and varicosities are treated with higher concentrations, up to 1 to 3 percent, to achieve adequate endothelial destruction within the larger venous lumen. The sclerosant is introduced through fine-gauge needles — typically 30 gauge for telangiectasias and 25 to 27 gauge for larger vessels — with careful aspiration performed prior to injection to confirm intraluminal placement and avoid inadvertent intraarterial or perivenous injection.
Foam sclerotherapy, which has become the preferred technique for larger varicosities and incompetent venous segments, involves the preparation of a sclerosant foam using the Tessari technique or a purpose-designed closed system, in which the liquid sclerosant is agitated with carbon dioxide or room air in a specific gas-to-liquid ratio to create a microfoam of defined bubble size. The foam formulation dramatically increases the surface area of sclerosant contact with the endothelium while simultaneously displacing intraluminal blood, enhancing efficacy at lower sclerosant concentrations and reducing systemic dilution. Foam sclerotherapy of larger truncal varicosities and perforating veins is performed under continuous real-time duplex ultrasound guidance — a technique designated ultrasound-guided foam sclerotherapy — allowing the proceduralist to directly visualize foam progression within the target vessel, confirm treatment of the intended segment, monitor for inadvertent deep venous entry, and halt injection immediately if foam is observed approaching the deep system.
During the injection, the patient may experience a mild burning or stinging sensation along the treated vein, which typically subsides within seconds and does not require analgesia in the majority of cases. Following completion of injections across the treatment session, the limb is dressed and graduated compression stockings are applied immediately, prior to the patient standing. Ambulation is encouraged promptly after the procedure, as calf muscle activation promotes deep venous return and reduces the risk of deep vein thrombosis by clearing any sclerosant that may have entered the deep system in minimal quantities.
Multiple treatment sessions are frequently required, particularly for extensive varicosity distributions or when telangiectasias are treated in a systematic, staged protocol. Sessions are typically spaced four to six weeks apart to allow interval assessment of response and to plan subsequent treatment of residual vessels.
Post-Procedure Care and Recovery
The recovery profile of sclerotherapy is one of its principal clinical advantages. Patients are ambulatory immediately following the procedure and are typically able to return to light daily activities on the same day. Graduated compression stockings — delivering 20 to 30 mmHg or higher compression as clinically indicated — are prescribed for continuous wear for a defined period, commonly ranging from one to three weeks depending on the vessel size treated, the volume of sclerosant injected, and institutional protocol. Compression serves the dual purpose of maintaining apposition of the treated venous walls to facilitate fibrosis and reducing the hydrostatic venous pressure that would otherwise promote recurrence.
Prolonged standing and strenuous physical exertion are restricted for one to two weeks post-procedure, while activities such as walking are actively encouraged. Air travel is generally deferred for a minimum of one week following foam sclerotherapy of larger vessels due to the transient increase in deep vein thrombosis risk. Hot baths, saunas, and direct sun exposure to treated areas are avoided for several weeks, as heat-induced vasodilation may impair the sclerotic response and photosensitivity of treated skin may result in hyperpigmentation.
Follow-up assessment is typically conducted at four to six weeks following each treatment session to evaluate the clinical and ultrasound response, identify any residual varicosities or treated vessel recanalization requiring retreatment, and manage any minor procedural complications. Patients are advised that the full cosmetic and clinical response, particularly in the case of telangiectasias, may not be apparent for several months as the obliterated vessels are gradually resorbed.
Risks and Complications
Sclerotherapy carries a well-defined and largely manageable complication profile. Among the most frequently encountered minor adverse effects is post-injection hyperpigmentation, which results from hemosiderin deposition within the treated vessel and surrounding dermis following intraluminal thrombus formation. This discoloration, often brown or tan in character, typically fades over months but may persist for up to one to two years in a minority of patients and is more common following treatment of larger vessels and in patients with darker skin phototypes.
Trapped blood, or coagulum, within sclerosed vessels presents as tender, indurated cord-like structures in the post-procedural period and is addressed through aspiration using a fine-gauge needle during follow-up visits, which accelerates resolution and reduces the risk of persistent hyperpigmentation. Matting — the development of fine new telangiectatic vessels in the vicinity of treated areas — represents a paradoxical vascular response to local inflammatory and angiogenic stimuli and affects a subset of patients; it may resolve spontaneously or require further treatment.
Deep vein thrombosis is an uncommon but clinically significant complication of sclerotherapy, particularly foam sclerotherapy of larger vessels, and is mitigated through prompt post-procedural ambulation, appropriate compression, and judicious limitation of injected foam volumes per session. Pulmonary embolism is rare but mandates awareness and patient education regarding symptoms. Neurological symptoms including visual disturbances, migraine-like headache, and transient chest tightness have been reported following foam sclerotherapy and are attributed to passage of microfoam through patent foramen ovale into the systemic circulation; they are typically transient but necessitate cessation of injection if observed.
Skin necrosis represents one of the more serious local complications and may occur as a consequence of extravasation of sclerosant into the perivenous tissue or inadvertent intradermal injection. It is more common with higher-concentration agents and requires careful injection technique, aspiration prior to injection, and use of the lowest effective sclerosant concentration. Anaphylaxis to sclerosant agents is exceptionally rare but remains a recognized possibility, necessitating availability of resuscitation equipment and anaphylaxis management protocols in all treatment settings.
Clinical Outcomes and Effectiveness
Sclerotherapy achieves high rates of clinical success and patient satisfaction when performed with appropriate patient selection, accurate hemodynamic assessment, and adherence to established injection technique. For telangiectasias and reticular veins, liquid sclerotherapy consistently demonstrates superior efficacy compared to laser treatment in multiple comparative studies, with clearance rates that are clinically significant and reproducible across experienced practitioners.
Ultrasound-guided foam sclerotherapy of truncal varicosities and incompetent saphenous segments achieves occlusion rates comparable to endovenous thermal ablation in a number of clinical series, though long-term recurrence rates are modestly higher, particularly at the saphenofemoral junction, necessitating more frequent follow-up and retreatment in some patients. Despite this, the absence of tumescent anesthesia, the simplicity of the technique, and the favorable cost and accessibility profile of foam sclerotherapy make it a preferred option for many patients with recurrent varicosities, anatomically challenging venous configurations, or contraindications to thermal procedures.
Symptom improvement — including reduction in pain, heaviness, swelling, and functional limitation — is reported by the large majority of appropriately treated patients. In the context of venous ulceration, eradication of superficial venous reflux through sclerotherapy, as part of a comprehensive venous insufficiency management program, has been demonstrated to contribute to ulcer healing and to reduce recurrence rates compared to compression therapy alone. The durability of results is influenced by the completeness of reflux source treatment, patient compliance with compression, and individual factors such as obesity, occupational venous stress, and hormonal influences.
Conclusion
Sclerotherapy remains a cornerstone of the interventional treatment of varicose veins and chronic venous insufficiency, offering a clinically effective, well-tolerated, and versatile approach applicable across the full spectrum of superficial venous disease. Its evolution from a largely empirical technique to one guided by duplex ultrasonography and evidence-based sclerosant protocols has substantially elevated its safety and diagnostic precision. When integrated into a structured venous treatment program — incorporating thorough duplex assessment, correction of axial reflux sources, and disciplined compression therapy — sclerotherapy delivers meaningful and sustained improvement in both the clinical and quality-of-life dimensions of venous disease. The procedure’s combination of clinical efficacy, procedural simplicity, and rapid patient recovery ensures its continued and central role in the modern interventional management of venous pathology.